Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alvogen Inc.

www.alvogen.com

Latest From Alvogen Inc.

Asia Deal Watch: Daiichi Sankyo Acquires Partial Asian Rights To Three Astellas Drugs

Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.

Deals Business Strategies

Alvogen Strikes Deals For Pfenex’ Teriparatide

Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.

Deals Value-Added Medicines

Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Pfenex Gets US Teriparatide Nod

Pfenex’ PF708 version of Forteo, submitted under the US 505(b)(2) hybrid regulatory pathway, has been approved by the FDA. Marketing partner Alvogen is expected to launch as soon as the FDA decides on the product’s equivalence rating after Pfenex submits a key study.

Approvals Regulation
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
      • Transdermal
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Luxembourg
  • Parent & Subsidiaries
  • Alvogen Inc.
  • Senior Management
  • Robert Wessman, Chmn. & CEO
    Joel Morales, CFO
    Thor Kristjansson, EVP, M&As
    Faysal Kalmoua, EVP, Portfolio
    Martina Feitzinger, EVP, Strategic Regulatory Affairs
  • Contact Info
  • Alvogen Inc.
    5 rue Heienhaff
    Senningerberg, NJ L-1736
    Luxembourg
Advertisement
Advertisement
UsernamePublicRestriction

Register